In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has ...

Public health researchers found no uptick in myositis associated with COVID-19 vaccines across Norway and Sweden in a controlled study, contradicting previous reports of the condition occurring in the ...

More than a third of Americans who were vaccinated against COVID-19 say they had side effects from the shot, and nearly half ...

Some 10% of adults who got the shot said that they were whacked by “major side effects,” and another 26% cited minor side effects.

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

Markets split between costly AI and undervalued sectors. Vaccine makers offer cheap valuations and steady income amid ...

The 12 months ending 31 October were volatile. But, after all was said and done, our international fund finished up 25%, our ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

More than a third of Americans who were vaccinated against COVID-19 say they had side effects from the shot, and nearly half suspect the vaccines killed many patients. The latest Rasmussen Reports ...